The Alzheimer’s Disease/Parkinson’s disease (AD/PD) annual conference began yesterday and will continue through Sunday, March 14. The virtual conference provides 6 full days of scientific presentations and symposia including a mix of pre-recorded oral presentations and live discussions with presenters. The NGI is represented by 10 of our own researchers who are presenting their recent […]
The NGI will be hosting a Workshop on the “Application of Machine Learning Tools to Omics in Neuroscience” on February 18, 2021. This full-day, virtual event will feature basic introductory sessions on Machine Learning, plenary lectures by invited speakers, oral presentations of submitted abstracts, and a round table discussion. Everyone is invited to register by […]
Drs. Harari, Benitez, Karch and Cruchaga leveraged biospecimens obtained from large and well-characterized human cohorts to identify a novel protective gene for Alzheimer disease, MS4A4A, that is also the major regulator of TREM2. This study provides a strong evidence of a biological link between TREM2 and MS4A4A in microglia in the context of AD. However, […]
Drs. Cruchaga and Karch are some of the Washington University investigators that received funding from Centene to perform molecular phenotyping of Alzheimer’s cases to identify novel molecular biomarkers and the identification of novel therapeutically targets. Specifically we plan to develop a personalized medicine approach to understand the effects of Alzheimer’s disease risk genes by combining […]
A study led Dr. Kauwe lab and in collaboration with Drs. Karch and Cruchaga identified rare variants in RAB10 that protects against Alzheimer’s Disease risk. In this study Dr. Karch lab performed the functional studies and Dr. Cruchaga lab contributed genetic data. A video explaining the findings can be found below:
Dr. Cruchaga discuss about the use of polygenic risk scores to predict individual level risk for Alzheimer and provide this data “direct-to-consumer”.
In collaboration with Alzforum Dr. Cruchaga analyses the impact of direct-to-consumer genetic testing.
Geneticists are inventing new ways to hunt AD variants that went undetected in GWAS and might shed light on AD pathogenesis. Many labs are searching for polymorphisms tied to specific quantitative traits. As Yuetiva Deming from Carlos Cruchaga’s group at Washington University, St. Louis, pointed out, GWAS identify risk variants but say nothing about how that risk manifests
R406W causes a specific form of frontotemporal dementia. We found that GABAergic dysfunction in postmortem tissue from people with sporadic FTD or progressive supranuclear palsy, but not in Alzheimer’s disease. Also highlighted in Alzforum: https://www.alzforum.org/news/research-news/stem-cell-model-nails-link-between-tauopathy-and-gabaergic-dysfunction
Great collaboration with Dr. Brett and Colona lab
The studies are funded by two grants totaling $7 million from the National Institute on Aging of the National Institutes of Health (NIH) and led by Carlos Cruchaga, an Professor of psychiatry and of neurology at the School of Medicine
Our computer method determined the proportions of each cell type — neurons, astrocytes, oligodendrocytes, microglial cells — and found that specific gene variants were linked to different proportions of these cell types.
Drs. Harari, Cruchaga and Karch received funded from the Chan Zuckerberg Initiative to understand the relationship between MS4A4A and TREM2
Our last study, published in Nature identified a new gene (PLD3) for Alzheimer’s disease.In this study, in which all the members from the lab (Peter Jin, Bruno Benitez, Yefei Cai, Jiyoon Choi and Breanna Cooper) and were involved, as well as several members from Dr. Goate lab, used exome-sequencing in late-onset (AD) families to identify […]